Medical update: HER2-Positive and triple-positive metastatic breast cancer

Between 15 and 20 percent of breast cancers are HER2-positive and test positive for a protein called human epidermal growth factor receptor 2, or HER2. In this video learn about the latest treatment options targeting HER2-positive metastatic breast cancer and hear about research in the pipeline. The recording discusses common concerns related to side effects of treatments and barriers to getting targeted medicine, as well as ways to overcome those barriers. The video is inclusive of those with triple-positive metastatic breast cancer.